SU 9516

Drug Profile

SU 9516

Alternative Names: SU9516

Latest Information Update: 03 Mar 2008

Price : $50

At a glance

  • Originator SUGEN
  • Developer Albert Einstein College of Medicine; SUGEN
  • Class Antineoplastics; Imidazoles; Indoles; Small molecules
  • Mechanism of Action Apoptosis stimulants; Cyclin-dependent kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 25 Jul 2000 Preclinical development for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top